As we approach 2026, we are taking the opportunity to reflect on the standout moments of the past year. At Oncology Central, we have collated the top 10 articles of 2025, including news pieces, conference coverage and opinion pieces.
What to look out for at ASH 2025
Coming in 10th place is our comprehensive conference guide for the ASH Annual Meeting and Exposition. The article provides agenda highlights for anyone looking to navigate the 8,200 abstracts presented at this key event in every hematologist’s calendar.
ASCO 2025 guide: breaking news and key themes
Ever popular, our ASCO conference guide once again makes our top 10 list. This roundup provides a breakdown of breaking news stories as well as key themes and social media highlights. Check out our ‘events coverage’ page for similar content from other major conferences throughout the year.
Artificial sweetener sucralose shown to dampen immunotherapy effectiveness
In at 8th place, news that sucralose, a popular artificial sweetener, hinders the effectiveness of anti-PD-1 based immune checkpoint inhibitor immunotherapy by interfering with the gut microbiome. The team also uncovered that probiotic supplements counteracted these effects, offering a practical workaround for patients who use sweeteners.
ASCO 2025: Inavolisib-palbociclib-fulvestrant improves overall survival for advanced breast cancer
The most popular news article from this year’s ASCO coverage focused on the Phase III INAVO120 trial, which demonstrated the potential of inavolisib with palbociclib and fulvestrant in improving survival outcomes for certain advanced breast cancer patients.
How transformational technologies are shaping the future of cancer care
An opinion piece exploring from AstraZeneca experts shines a light on the power of transformational technologies in revolutionizing clinical trial design. The article explores computational pathology, ctDNA and multi-omics potential in advancing precision oncology and provides insights on integrating these innovations into routine clinical practice.
Could COVID-19 mRNA vaccines help treat cancer?
Next up, a news story from ESMO 2025 that outlined how researchers are getting one step closer to developing a universal cancer vaccine. In the words of co-author Elias Sayour (University of Florida, FL, USA): “The implications are extraordinary – this could revolutionize the entire field of oncologic care.”
Bridging the gaps: how strategic charity partnerships are transforming head and neck cancer care
Taking the 4th spot, is an opinion piece from Danni Heath at the Get A-Head Charitable Trust, which examines the growing head and neck cancer crisis. She highlights critical treatment delays and care inequalities while outlining how strategic charitable partnerships are addressing these challenges through patient-centered approaches.
Burnout: strategies and tools for clinicians
Nabbing 3rd place, our webinar brought together leading healthcare experts to tackle physician burnout in oncology. The session explored root causes, provided practical steps for oncologists, and showcased innovative institutional strategies from around the globe. The webinar is available to view on demand here.
World-first trial highlights survival benefits of exercise for colon cancer
Our most-read news piece of the year showcased the real-world impact of a healthy lifestyle on long-term patient outcomes. The groundbreaking trial of 889 colon cancer patients across six countries found that structured exercise programs significantly improved survival rates.
What do Trump’s NIH restrictions mean for cancer research?
At the start of 2025, shockwaves ran through the scientific community as the Trump administration announced indefinite suspensions of research-grant reviews. Throughout the year, we’ve published articles focused on achieving equitable cancer care amid political turmoil. At Oncology Central, we remain committed to supporting the cancer research community by providing a free platform for oncologists to stay up-to-date with the latest developments.
We hope you’ve enjoyed our round-up of the most-read stories from across Oncology Central in 2025. Interested in more ‘must-read’ content? View our immunotherapy, conference coverage, prevention and screening content by clicking the links.